Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 652 clinical trials
featured
Early-stage Hepatocellular Carcinoma

People with liver cirrhosis and recently diagnosed (not yet treated) early-stage hepatocellular carcinoma are asked to participate in a research study being conducted by Montefiore Medical Center

  • 54 views
  • 23 Nov, 2020
  • 1 location
featured
CALGB 80802: A Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).

CALGB 80802: A Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).

  • 84 views
  • 08 Nov, 2020
  • 1 location
featured
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with …

advanced cancer
cancer
  • 128 views
  • 14 Dec, 2020
  • 4 locations
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

Hepatitis B (+) associated advanced hepatocellular carcinoma. YIV-906 (PHY906, KD018) is an immune system modulator. Clinical and preclinical research suggests that YIV-906 could act to enhance the

  • 2 views
  • 27 Jan, 2021
  • 32 locations
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

The purpose of this study is to evaluate the safety and efficacy of fixed dose coformulated pembrolizumab/quavonlimab (MK-1308A) plus lenvatinib in a first line (1L) hepatocellular carcinoma

  • 0 views
  • 11 Apr, 2021
  • 7 locations
  • 9 views
  • 23 Jan, 2021
  • 35 locations
A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

The purpose of this study is to evaluate the efficacy of 48-week study intervention with JNJ-73763989+JNJ-56136379+nucleos(t)ide analog (NA) regimen compared to NA alone assessed by HBsAg levels. This study is part of HepB Wings Platform Trial (PLATFORMPAHPB2001).

  • 6 views
  • 01 Mar, 2020
  • 32 locations
Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis

The purpose of this study is to investigate safety and potential therapeutic benefits for patients with hepatocellular carcinoma by transcatheter chemoembolization with the recombinant

transcatheter arterial chemoembolisation
angiogenesis inhibitor
chemoembolization
TACE
measurable disease
  • 2 views
  • 07 Nov, 2020
  • 1 location
Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)

For the majority of patients, metastatic HCC is incurable and patients should be considered candidates for clinical trials when appropriate. Till recently there was no worldwide, approved

sorafenib
cancer
gemcitabine
measurable disease
systemic therapy
  • 14 views
  • 07 Nov, 2020
  • 1 location
Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)

A randomized, double-blind, controlled trial was conducted evaluating the efficacy of Oligo-Fucoidan with the molecular weight ranged from 500 to 800 Da. as a supplemental therapy in patients with metastatic colorectal cancer. The previous study results demonstrate the advantages of Oligo-Fucoidan in improving the disease control rate. The previous study …

  • 0 views
  • 19 Feb, 2021
  • 1 location